Claude Bernard University Lyon 1-ko ikertzaileekin lankidetzan egindako argitalpenak (27)

2024

  1. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

    Haematologica, Vol. 109, Núm. 3, pp. 867-876

  2. Acute and two-week effects of neotame, stevia rebaudioside M and sucrose-sweetened biscuits on postprandial appetite and endocrine response in adults with overweight/obesity—a randomised crossover trial from the SWEET consortium

    eBioMedicine, Vol. 102

  3. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine

    The Lancet Respiratory Medicine, Vol. 12, Núm. 4, pp. 305-322

  4. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 14, pp. 1612-1618

2023

  1. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

    Blood

  2. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

    American Journal of Hematology, Vol. 98, Núm. 11, pp. 1699-1710

2022

  1. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 242-251

  2. Six-Year Results from RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

    Journal of Clinical Oncology

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium

    Blood Cancer Journal, Vol. 10, Núm. 7

  2. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

    The Lancet, Vol. 396, Núm. 10262, pp. 1574-1584

  3. Procedural and Short-Term Results With the New Watchman FLX Left Atrial Appendage Occlusion Device

    JACC: Cardiovascular Interventions, Vol. 13, Núm. 23, pp. 2732-2741

  4. Prognostic gene expression signature for high-grade serous ovarian cancer

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1240-1250

  5. Safety and efficacy of intravenous thrombolysis in stroke patients on prior antiplatelet therapy in the WAKE-UP trial

    Neurological Research and Practice, Vol. 2, Núm. 1

2019

  1. Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma

    Journal of Clinical Oncology

2018

  1. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

  2. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

    The Lancet Haematology, Vol. 5, Núm. 8, pp. e359-e367

2017

  1. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

    Journal of Clinical Oncology, Vol. 35, Núm. 22, pp. 2473-2481

2016

  1. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial

    Journal of Clinical Oncology, Vol. 34, Núm. 22, pp. 2575-2582

2014

  1. Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

    Blood